CRH reports Q2 revenue growth with higher profits and acquisition activity

Jim Mintern Chief Executive Officer and Executive Director CRH
Jim Mintern Chief Executive Officer and Executive Director - CRH
0Comments

CRH has reported its financial results for the second quarter of 2025, showing growth in key areas. The company’s total revenues reached $10.2 billion, an increase of 6% compared to the same period last year. Net income rose by 2% to $1.3 billion, while diluted earnings per share increased by 3% to $1.94.

Adjusted EBITDA for the quarter was $2.5 billion, representing a 9% rise from the previous year and resulting in an adjusted EBITDA margin of 24.1%. CRH attributed this performance to strong demand, effective pricing strategies, and contributions from recent acquisitions.

The company invested $1 billion in 19 acquisitions so far this year and agreed to acquire Eco Material Technologies for $2.1 billion as part of its cementitious growth strategy. A new quarterly share buyback tranche of $0.3 billion will begin after completing $0.8 billion in buybacks year-to-date.

CRH declared a quarterly dividend of $0.37 per share, up 6% from last year.

Jim Mintern, Chief Executive Officer, stated: “Our strong second quarter performance was driven by favorable underlying demand, disciplined commercial management and further contributions from acquisitions. CRH’s proven strategy continued to drive higher sales, profits and Adjusted EBITDA margins*, while our robust balance sheet and financial capacity enabled us to allocate approximately $3 billion to growth investments and capital returns year-to-date. We completed 19 acquisitions year-to-date and continue to see an active pipeline of opportunities to further strengthen our market-leading positions in attractive growth markets. Underlying demand in our key end-use markets remains positive and we are pleased to raise our guidance for 2025.”

Looking ahead, CRH expects activity across its main markets to remain positive through the rest of the year and forecasts full-year net income between $3.8 billion and $3.9 billion with adjusted EBITDA projected at $7.5-$7.7 billion.

Further details on non-GAAP measures can be found in the company’s supplementary information.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.